key: cord-0706456-w6bu18zy
authors: Luan, Binquan; Huynh, Tien
title: Crystal‐structures‐guided design of fragment‐based drugs for inhibiting the main protease of SARS‐CoV‐2
date: 2021-10-21
journal: Proteins
DOI: 10.1002/prot.26260
sha: 0608ad9fe793179b98f17617c19ce8de3e8a7ab8
doc_id: 706456
cord_uid: w6bu18zy

Since the beginning of the COVID‐19 pandemic, scientists across the globe are racing to find a cure for the highly contagious infectious disease caused by the SARS‐CoV‐2 virus. Despite many promising ongoing progress, there are currently no FDA approved drug to treat infected patients. Recently, the crowdsourcing of drug discovery for inhibiting the main protease (Mpro) of SARS‐CoV‐2 have yielded a plenty of drug fragments resolved inside the active site of Mpro via the crystallography method. Following the principle of fragment‐based drug design (FBDD), we are motivated to design a potent drug candidate (named B19) by merging three fragments JFM, U0P, and HWH. Through extensive all‐atom molecular dynamics simulation and molecular docking, we found that B19 among all designed ones is most stable inside the Mpro's active site and the binding free energy of B19 is comparable to or even a little better than that of a native protein ligand processed by Mpro. Our promising results suggest that B19 and its derivatives can potentially be efficacious drug candidates for COVID‐19.

Mpro. Additionally, dozens of fragment drugs were shown to be covalently bound to C145 inside Mpro, as listed on the website of the COVID Moonshot open initiative (https://postera.ai/covid), a project aiming to accelerate the development of antiviral drugs that can inhibit the SARS-CoV-2's Mpro with joined forces from scientists around the world. 10 Besides the covalently bound ligands, dozens of noncovalently bound drug fragments that span the entire active site of the SARS-CoV-2's Mpro have also been identified using large scale crystallographic and mass-spectrometry screening. 11 These structures (listed on COVID Moonshot website and deposited in Protein Data Bank) reveal an exceptionally rich set of information, with extensive opportunities for fragment-based drug discovery (FBDD) for inhibiting the SARS-CoV-2 Mpro.

Generally, FBDD provides an effective alternative to explore the chemical space for binding to a specific target protein. Since its inception two decades ago, FBDD has attracted a lot of interest from researchers and emerged as a mainstream approach in the pharmaceutical industry for reducing attrition and finding high-quality lead candidates as a part of the drug discovery process. 12 FBDD is based on screening very small chemical compounds (fragments) with low molecular weights which could bind only weakly to the biological target as starting points. The binding affinity between the initial fragment hits to their target is usually in a μM-mM range. 13 This is due to the fact that there are fewer heavy atoms in the fragments to form multiple attractive interactions with the protein when compared with larger molecules. 14 Once the fragment hits are identified, their potency can be enhanced by applying fragment linking, merging, or growing strategies to form drug-like leads optimized for potential clinical candidates.

Given a plethora of drug fragments resolved in the Mpro's crystal structure 11 and the established protocol for FBDD, in this work, we are motivated to design a potent drug molecule structurally merged from several of these drug fragments for inhibiting Mpro. Complimentary to experimental efforts, in silico approaches such as the all-atom molecular dynamics (MD) 15, 16 and docking 17 methods have been widely used to investigate the molecular mechanism of proteins as well as the ligand-protein interaction, and proven to produce results consistent with experimental ones. Here, we carried out MD simulations to explore a total of 19 designed ligands based on the FBDD approach and compare them with a native ligand (a protein peptide) previously resolved in the crystal structure of Mpro of SARS-CoV-1. 18 Out of these 19 designed ligands, we found that the binding affinity of a designed drug molecule (named B19) to Mpro is comparable or even slightly better than that of the native ligand, suggesting that B19 is highly promising for inhibiting Mpro of SARS-CoV-2.

Among the 50 known non-covalently bound fragments inside the active site, 11 we selected three ligands JFM, U0P, and HWH ( Figure 1A ) that bind the active site at different locations ( Figure 1B-D) and contain their own specific features as described in the following. Namely, from head to tail, JFM contains a methanesulfonamide and a benzene groups; U0P contains a cyclopropane and a carbonyl groups in the head part and an isoxazole group in the tail part; HWH contains an indole group with an attached fluorine atom (pink, Figure 1A ) in the head part and an acetamide in the tail part. These chemical groups form either hydrogen bonds or hydrophobic interactions with Mpro's residues inside the active site, stabilizing these bound fragments.

Following previous studies, 19 the active site of Mpro is composed of four key subsites that are respectively labeled as S1 0 , S1, S2, and S4 ( Figure 1B ). As shown in Figure 1B -D, the fragment U0P binds the S1 and S1 0 subsites, and the fragments JFM and HWH bind the S2 and S4 subsites, respectively. Interestingly, a co-crystallization agent dimethyl sulfoxide (DMSO) is also present inside the active site (S1) along with HWH as shown in Figure 1D . Due to their proximity ( Figure 1E) Figure 1E being the most stable one (evaluated from our MD simulations) and the rest (from B1 to B18) shown in Figure S1 . In our design of B19, we first merged JFM and HWH together because their benzene rings overlap with each other. After that, we employed the linker molecule shown in Figure 1E to bridge the merged compound and U0P. In B19, the carbon atom attached to the benzene ring (originally in JFM) was replaced by a nitrogen atom, which can form a stable three-way junction, maintaining the overall conformation of B19 inside the active site of Mpro (see below). Importantly, the catalytic dyad comprising H41 and C145 is completely covered by the designed B19 molecule.

Note that the Mpro's active site is formed by two protein domains, residues 1-100 (I) and residues 101-200 (II). The subsites S1, S2 are, respectively, in domains II and I, while the subsites S1 0 and S4 are at the interface of domains I and II. Therefore, the active site of Mpro is not rigid and can deform slightly to harbor a ligand (such as B19) bridging two Mpro domains. Generally, the host's flexibility is amenable to the FBDD method, that is, capable to accommodate a merged complex containing slightly displaced fragments.

We performed MD simulations to verify the stability of each designed drug molecule (from B1 to B19) bound inside the active site. Additionally, the isoxazole group (present in the S1 subsite) could turn 180 from time to time. Thus, different from the one shown in Figure 2B ,C, the N and O atoms in the five-membered isoxazole ring could also be in contact with the Mpro surface ( Figure 1C and Movie S1).

From the simulation trajectories, we calculated the root mean square deviations (RMSD) for backbone atoms in the monomer (of Mpro) that harbors the B19. Figure 3A shows that after about 75 ns RMSDs from two independent MD simulations saturate around 1.7 Å, suggesting that the Mpro's crystal structure was properly equili- We further calculated the pairwise interaction energy between B19 and Mpro, including the van der Waals (vdW, Figure 3C ) and electrostatic ( Figure 3D ) ones. Over the entire 190 ns, both the vdW and electrostatic potential energies are nearly constant for both simulations (Sim-1 and Sim-2), with the electrostatic ones ( Figure 3D) showing larger fluctuations partly due to the omission of interfacial water molecules in these calculations. In comparison, results for Sim-2 are slightly better (more negative) than those for Sim-1, with the vdW energy about À68.3 kcal/mol and the electrostatic one about À12.3 kcal/mol. Besides demonstrating the binding stability of B19 in the active site, these results will be further used in the MM/GBSA calculations to obtain the binding free energy of B19 (see below).

In the other 18 designs (B1-B18) as shown in Figure S1 , these drug molecules with unsuccessfully designed linker molecules moved more or less away from their initial positions during MD simulations, that is, at least one fragment in each designed drug molecule either rotated or shifted away from the one as seen in the crystal environment. For example, observed in two independent MD simulations, the U0P fragment in B15 was not stable and moved out of the S1 and S1 0 subsites, however, the other two fragments of B15 remained inside the subsites S2 and S4, respectively, indicating the problematic design of the link molecule in B15 ( Figure S1 ).

In Figure 4 , we highlight key coordinations between B19 and Mpro to unveil the molecular mechanism of the binding. In Figure 4A , and C145, which pins the entire U0P fragment in the subsites S1 and S1 0 ( Figure 2B ). Remarkably, this same local coordination can also be found in the complex of Mpro and O6K (PDB code: 6LU7). Furthermore, through hydrophobic interactions the cyclopropane group (originally in U0P) was stabilized by hydrophobic interactions with residues C145, L27, and T25 of Mpro. The isoxazole group (originally in U0P) occupies the subsite S1, a pocket formed by residues H163, N142, L141, F140, E166 as well as the residue S1 in the N-terminal of the other protein monomer (purple, Figure 4D ). There is no hydrogen bond formed in this local interaction, which is consistent with the observation that the isoxazole group can rotate from time to time (see Movie S1). Taking all together, the isoxazole group and the methanesulfonamide group are, respectively, hosted by the domains II and I, while the cyclopropane group and the indole group lie between the domains I and II (see Figure 2B , C). Thus, fitting nicely inside the active site, B19 appears to act like a glue bonding the two protein domains together.

One restriction of the above MD simulation is that we cannot Figure S2c ), which is slightly larger than the one for B19 due to a few flexible residues outside the active site. Overall, the native ligand is stable inside the active site, which is also demonstrated in Movie S2.

As shown in Figure 6A , the native ligand is stabilized by forming two antiparallel beta sheets with residues (e.g., T26) in the protein domain I and with residues (e.g., E166) in the protein domain II. Inside the active site, Q6 (of the native ligand) occupies the S1 subsite; S7

and G8 are in the subsite S1 0 ; A3 and S2 are in the subsite S4; and L5

occupies the subsite S2. The side chain of V4 is oriented toward outside the active site ( Figure 6B ). The other residues T1, F9, R10, and K11 are all outside of the active site. Figure 6C highlights detailed interactions between the native ligand and Mpro. We found that the C=O group in the backbone of Q6, similar to the same group of B19 as shown in Figure 4A , also formed two hydrogen bonds with G143 and C145. It is worth noting that Q6 is very specific to the subsite S1, as shown in many other native protein strands for Mpro of SARS-CoV-1. 22 However, the side chain of Q6 (also the isoxazole group in B19) neither forms any hydrogen bond nor has any hydrophobic interactions with the nearby Mpro residues. Presumably, the orientation of the Q6's side chain and the isoxazole group in B19 inside the subsite S1 enables the neighboring C=O group to form strong hydrogen bonds with G143 and C145.

Notably, S7 forms a hydrogen bond with H41. The latter also forms a hydrogen bond with the NH group in the JFM fragment in B19

( Figure 4B ). Additionally, G8 forms a hydrogen bond with T26 in Mpro via their backbones, forming antiparallel β-sheets. All these hydrogen bonds tightly positioned the native ligand in the front of the catalytic center C145, illustrating the molecular mechanism of catalytic processing of the bound peptide.

The binding of L5 inside the S2 subsite is also highly conserved among all native protein strands in Mpro of SARS-CoV-1. 22 As shown in Figure 6C , L5 is sandwiched between two hydrophobic residues M49 and M165 in Mpro. In contrast, the benzene ring in the HWH fragment in B19 resides between M49 and M165 ( Figure 4C ).

Although the side chain of V4 is outside the active site, its backbone Figure 3C ,D, which is À80.6 kcal/mol (Table 1) . After removing all restraints, the production run was carried out in the NVT ensemble. This same protocol was successfully applied to study the molecular mechanism of SARS-CoV-2's variants: Alpha 30 and Beta. 31 The CHARMM36 force field 32 was chosen for proteins (Mpro and the native ligand); the TIP3P model 33, 34 was chosen for water; the standard force field 35 was used for ions. The force field for the designed ligands were obtained from SwissParam. 36 We provided the .psf and .pdb files for B19 in the Appendices S2 and S3. The periodic boundary conditions (PBC) were applied in all three dimensions. Longrange Coulomb interactions were calculated using particle-mesh Ewald (PME) full electrostatics with the grid size about 1 Å in each dimension. The van der Waals (vdW) energies between a pair of atoms were calculated using a smooth (10-12 Å) cutoff. The temperature T was maintained at 300 K by applying the Langevin thermostat, 37 while the pressure was kept constant at 1 bar using the Nosé-Hoover method. 38 With the SETTLE algorithm 39 applied to keep all bonds rigid, the simulation time-step was set to be 2 fs for bonded and non-bonded (e.g., vdW, angle, and dihedral) interactions, and electric interactions were calculated every 4 fs, with the multiple time-step algorithm. 

We employed Autodock Vina, 20 

A new coronavirus associated with human respiratory disease in China

Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome

Severe respiratory illness caused by a novel coronavirus

Remdesivir for the treatment of Covid-19-preliminary report

Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial

The SARS-CoV-2 main protease as drug target

Structure of Mpro from COVID-19 virus and discovery of its inhibitors

Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors

Structural basis for the inhibition of SARS-CoV-2 main protease by antineoplastic drug Carmofur

Crowdsourcing drug discovery for pandemics

Crystallographic and electrophilic fragment screening of the SARS-CoV-2 main protease

Introduction to Fragment-Based Drug Discovery

The rise of fragment-based drug discovery

The 'rule of three' for fragment-based drug discovery: where are we now?

Molecular dynamics simulations of biomolecules

Challenges in proteinfolding simulations

Comprehensive evaluation of ten docking programs on a diverse set of protein-ligand complexes: the prediction accuracy of sampling power and scoring power

Structures of two coronavirus main proteases: implications for substrate binding and antiviral drug design

Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease

AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading

In silico exploration of molecular mechanism of clinically oriented drugs for inhibiting SARS-CoV-2's main protease

SARS-CoV 3CL protease cleaves its C-terminal autoprocessing site by novel subsite cooperativity

MM/GBSA binding energy prediction on the PDBbind data set: successes, failures, and directions for further improvement

Computationally efficient methodology for atomic-level characterization of dendrimer-drug complexes: a comparison of amine-and acetyl-terminated PAMAM

Automated extraction of chemical synthesis actions from experimental procedures

Predicting retrosynthetic pathways using transformer-based models and a hyper-graph exploration strategy

Free Energy Calculations

Combined computationalexperimental approach to explore the molecular mechanism of SaCas9 with a broadened DNA targeting range

Scalable molecular dynamics with NAMD

Enhanced binding of the N501Y-mutated SARS-CoV-2 spike protein to the human ACE2 receptor: insights from molecular dynamics simulations

Insights into SARS-CoV-2's mutations for evading human antibodies: sacrifice and survival

All-atom empirical potential for molecular modeling and dynamics studies of proteins

Comparison of simple potential functions for simulating liquid water

Simulation of activation free energies in molecular systems

Finite representation of an infinite bulk system: solvent boundary potential for computer simulations

SwissParam: a fast force field generation tool for small organic molecules

Computer Simulation of Liquids

Topology representing networks

SETTLE: an analytical version of the SHAKE and RATTLE algorithm for rigid water molecules

Reversible multiple time scale molecular dynamics

Theory and applications of the generalized born solvation model in macromolecular simulations

Crystal-structuresguided design of fragment-based drugs for inhibiting the main protease of SARS-CoV-2

The authors declare no conflicts of interest.

The peer review history for this article is available at https://publons. com/publon/10.1002/prot.26260.

The data that supports the findings of this study are available in the supplementary material of this article.

https://orcid.org/0000-0002-9414-5379